Skip Over Navigation Links

Research

Industry-Provided Agents

medicines

The private sector holds many of the agents and data needed for efficient drug rescue and repurposing. However, because innovative ideas for new uses of these resources come from a variety of organizations, including NIH and the broader biomedical research community, public-private partnerships and collaborations are critical to this research. Through the Discovering New Therapeutic Uses for Existing Molecules program, pharmaceutical companies provide researchers with access to their partially developed therapeutic candidates (referred to as agents) and related data.

These agents have undergone significant pre-clinical and safety testing in humans and are ready for additional testing in patient populations. Making information about these promising agents available to the research community gives scientists an opportunity to explore potential new therapeutic uses in previously unexplored disease areas. The collaborating pharmaceutical companies have identified agents suitable for adult indications as well as for pediatric indications.

Table of Agents for Adult Indications

Code Number & Link to More InformationMechanism
of Action
Original Development Indication(s)Route of Administration Formulation Available
(CNS Penetrant+)
AZD401711-beta hydroxysteroid dehydrogenase type 1 inhibitorDiabetesOral
(Low)
RWJ-445380Cathepsin S inhibitorPsoriasis
Rheumatoid arthritis
Oral
SAR114137Cathepsin S inhibitorChronic pain (osteoarthritis, neuropathic, low back)Oral
(Maybe)
CNTO-888
Carlumab
Chemokine (C-C motif) ligand 2 selective human IgG1 kappa monoclonal antibodyIdiopathic pulmonary fibrosisIntravenous
(No)
AZD9291Epidermal growth factor receptor (EGFR) tyrosine kinase sensitizing and T790M resistance mutations inhibitorNon-small cell lung cancerOral
(Unknown)
JNJ-31001074
Bavisant
Histamine type 3 receptor antagonistAttention deficit hyperactivity disorderOral
(Yes)
SAR110894Histamine type 3 receptor antagonistSymptomatic treatment of Alzheimer's diseaseOral
(Yes)
AZD2014Mammalian target of rapamycin serine/ threonine kinase (dual TORC1 and TORC2) inhibitorSolid tumorsOral
(Unknown)
AZD8529Metabotropic glutamate receptor 2 positive allosteric modulatorSchizophreniaOral
(Yes)
PF-03882845Mineralocorticoid receptor antagonistDiabetic nephropathyOral
AZD6765
Lanicemine
N-methyl-D-aspartate receptor open-channel blockerMajor depressive disorderIntravenous
(Yes)
AZD2624Neurokinin-3 receptor, tachykinin receptor 3 antagonistSchizophreniaOral
(Low)
AZD9668Neutrophil elastase inhibitorChronic obstructive pulmonary disease
Cystic fibrosis
Oral
(Low)
PF-03049423Phosphodiesterase type 5 inhibitorStroke recoveryOral
(Yes)
AZD1208Proviral integration Moloney virus serine/threonine kinase family inhibitorAcute myeloid leukemia
Advanced solid tumors
Malignant lymphoma
Oral
(Yes)
CE-224535Purinergic receptor 2 antagonistRheumatoid arthritis
Osteoarthritis
Oral
AZD9150Signal transducer and activator of transcription 3 antisenseHepatocellular carcinomaIntravenous
(Low)
AZD1775Wee1 G2 checkpoint kinase inhibitorAdvanced solid tumorsOral
(Unknown)

+CNS penetrant: Yes, no,maybe, low or unknown.

Table of Agents for Pediatric Indications

Code Number & Link to More InformationMechanism
of Action
Original Development Indication(s)Route of Administration Formulation Available
(CNS Penetrant+)
AVE5530
Canosimibe
Acyl-coenzyme A: cholesterol O-acyltransferase inhibitorHypercholesterolemiaOral
(No)
SSR149744
Celivarone
Cation channel blockerSupraventricular (atrial fibrillation) and ventricular arrhythmia Oral
AZD1981Chemoattractant receptor-homologous molecule expressed on Th2 cells antagonist (prostaglandin D2 receptor antagonist)Asthma
Chronic obstructive pulmonary disease
Oral
(Low)
AZD7325Gamma-aminobutyric acid receptor A alpha 2 & 3 positive modulatorGeneral anxiety disorderOral
(Yes)
AZD3355
Lesogaberan
Gamma-aminobutyric acid receptor B agonistGastroesophageal reflux diseaseOral
(Low)
JNJ-31001074
Bavisant
Histamine type 3 receptor antagonistAttention deficit hyperactivity disorderOral
(Yes)
PF-03654746Histamine type 3 receptor antagonistTourette syndrome
Narcolepsy
Cognition
Attention deficit hyperactivity disorder
Allergic rhinitis
Oral
(Yes)
SAR152954Histamine type 3 receptor antagonistExcessive daytime sleepinessOral
(Yes)
AZD6765
Lanicemine
N-methyl-D-aspartate receptor open-channel blockerMajor depressive disorderIntravenous
(Yes)
AZD9668Neutrophil elastase inhibitorChronic obstructive pulmonary disease
Cystic fibrosis
Oral
(Low)
JNJ-39393406Nicotinic acetylcholine receptor, α7 positive allosteric modulatorCognitive impairment associated with schizophreniaOral
(Yes)
AZD1775Wee1 G2 checkpoint kinase inhibitorAdvanced solid tumorsOral
(Unknown)

+CNS penetrant: Yes, no,maybe, low or unknown.